Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Advanced Heart Failure and Transplant
When would you consider endomyocardial biopsy for newly noted LVH with genetic testing significant for MYH7 mutation but also a TTR VUS also present?
Related Questions
How do you think about using contraction alkalosis as a mark of achieving goal diuresis?
What are your preferred echocardiographic parameters and goals for weaning RVAD support?
What is your approach when a patient has concomitant acute decompensated heart failure and rapid atrial fibrillation?
What are your first-line vasopressors of choice for the management of acute severe aortic regurgitation and persistent hypotension/shock?
Would you ever consider switching a patient with an LVAD from warfarin to Eliquis, such as in the setting of recurrent GI bleeds?
In patients with moderate calcific mitral stenosis, possible HFpEF and dyspnea on exertion, how would you differentiate the etiology of the symptoms?
How do you use NT-proBNP in patients with chronic kidney disease or end-stage kidney disease, given that these conditions can affect NT-proBNP levels?
Do you ever consider sodium supplementation to augment diuresis in patients hospitalized with decompensated heart failure, as discussed in a recent systematic review and meta-analysis?
For patients admitted with acute decompensated heart failure, do you wait until the patient is euvolemic before ordering a TTE?
For patients with HFrEFand consitent SBP readings in the 90s with baseline CKD and borderline elevated K within the high 5 range, how do you prioritize which medications to uptitrate for GDMT when BP, labs, renal function provide limitations?
